Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GYRE THERAPEUTICS, INC.GYRE · Entity 5247 | Director · Chief Executive Officer | August 14, 2024 | August 17, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GYRE THERAPEUTICS, INC.
Report date August 14, 2024 · Filed August 17, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.98 · Expires 2034-08-14 | Direct | 341,000 |
Reported balance
After 2024-08-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-08-14 · Grant · Acquired 341,000 · Balance 341,000 F1: This option represents a right to purchase a total of 341,000 shares of the Issuer's common stock, 25% of which will vest on August 14, 2025, with the remaining vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option represents a right to purchase a total of 341,000 shares of the Issuer's common stock, 25% of which will vest on August 14, 2025, with the remaining vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 14, 2024 Filed Aug 17, 2024 00:50 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 341,000 | $0.00 Strike: $9.98 | $0.00 |
DisclosureSEC source: 0001140361-24-037705 · form4.xml · derivative · entry 1 Ying Han · CIK 0001987630 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 341,000 Underlying: Common Stock · 341,000 shares Expires 2034-08-14 F1 · derivative.exercise_date: This option represents a right to purchase a total of 341,000 shares of the Issuer's common stock, 25% of which will vest on August 14, 2025, with the remaining vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| October 31, 2023 Filed Nov 1, 2023 10:15 UTC | GYRE THERAPEUTICS, INC. GYRE · Entity 5247 | GrantStock Option (Right to Buy) · Derivative | 1,866 | $0.00 Strike: $6.93 | $0.00 |
DisclosureSEC source: 0001140361-23-050615 · form4.xml · derivative · entry 1 Ying Han · CIK 0001987630 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,866 Underlying: Common Stock · 1,866 shares Expires 2033-10-31 F1 · derivative.exercise_date: These options vest as to one-third on each of the first, second and third anniversaries of October 31, 2023, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.